Google didn’t build the best flu forecasting model. It built a tool that built the model โ and that distinction is where the real story lives.
This is a forecasting result, not a clinical or public-health one. Nothing below claims any effect on patient care, hospital preparedness or response planning, and nothing below is medical advice.The ranking covers one season on one metric and comes from Google’s own account; the CDC evaluation page returns a 403 to this publication, so it has not been checked independently. Nothing here is investment advice.
Google published a result from the CDC’s FluSight forecasting tournament on September 30, 2026, in a research blog post by Zahra Shamsi. Of 39 eligible models, Google’s entry best matched observed US hospital admissions across the 2025โ26 flu season โ October through May โ at the current week and three weeks out.
The model was not hand-built by Google researchers. It was produced by ERA โ Empirical Research Assistance โ an AI tool that generates optimization algorithms across a range of scientific fields. ERA produced the algorithm. The algorithm won the tournament. Google’s research on ERA has been published in Nature, and the tool is now going to trusted testers.
One transparency note before going further: this publication could not reach the CDC evaluation page, which returns a 403. The ranking therefore rests on Google’s own account and has not been independently verified here. The post itself lists no stated caveat or limitation โ which is an observation about the post, not evidence of a problem with the underlying work, since the tournament is public in principle.
The key insight: ERA did not win a flu competition. ERA generated an algorithm that won a flu competition. That one-level remove is the entire businessstory. The flu result is a sample output. ERA is the product.
The post does not give the margin over second place or the scoring metric, so the size of the win is not established here – only its rank.
What the Result Does Not Establish
The post does not report the margin over second place. It does not name the scoring metric the tournament used. It does not identify which of the 38 other entrants were in this comparison โ FluSight draws academic, government, and private participants, and the field composition matters for reading the result.
Without the margin, a dominant win and a near-tie look identical from outside. This publication is not treating the rank as a measure of how much better the algorithm was, because the post does not say.
Also absent: how ERA works internally, who the trusted testers are, whether the flu model is used operationally anywhere, and how the model performed in earlier seasons. One season is one draw.
Nothing here is a health claim of any kind. The post reports a forecasting result, not a deployment. No inference about hospital preparedness, patient care, or public-health outcomes is supported by this result, and none is made here.
The Structural Read
The standard way to read this story is: Google built the best flu model. That reading is not wrong, but it undersells what Google is actually signaling.
Building the best flu model is a claim about flu. Building a generator whose output wins a flu tournament is a claim about the generator. Those are different assets with different economics.
One domain win is a data point. The strategic frame is that ERA could, in principle, be pointed at other forecasting problems โ and the Nature publication and the trusted-tester rollout are organized around ERA, not around influenza. That is Google telling you where it thinks the value is.
The limit on this reading needs stating plainly. One public result in one field is not evidence of generalization. ERA’s post describes it as working across a range of scientific fields. That may prove true. It is not established by one season of flu forecasting data, and this publication is not asserting it.
Three Implications
IMPLICATION 1 โ THE ASSET IS THE METHOD-WRITER A domain win is evidence about ERA, not just about flu forecasting. If the generator can be aimed at other structured prediction problems, the flu result becomes a proof-of-concept rather than a specialty. Google’s publication and tester strategy both point there. One result does not confirm it; the framing invites that reading.
IMPLICATION 2 โ BENCHMARK SELECTION IS A STRATEGIC ACT FluSight is a public, structured, multi-entrant tournament. It is more verifiable than most vendor benchmark announcements โ in principle. The 403 on the CDC evaluation page means this publication could not check the ranking directly. Choosing a public competition over an internal benchmark is a credibility move. The independent verification piece is incomplete here, and readers should note that.
IMPLICATION 3 โ ONE SEASON IS A THIN EVIDENCE BASE The result covers the 2025โ26 season only. No earlier season data is reported. No margin over second place is given. No scoring metric is named. A result this sparsely documented is a starting point for scrutiny, not a conclusion. The underlying tournament is auditable; that audit has not been done here.
Business Engineer Framework
Product Overhang Doctrine
ERA is a capability that has been maturing inside Google Research. The FluSight win is the first external proof point โ the moment the overhang surfaces. The Map of AI framework maps where tools like ERA sit in the broader AI stack: not at the application layer, and not at the foundation model layer, but in the methods and optimization layer between them. That positioning shapes who ERA competes with and who it enables.
Google topped a 39-model CDC flu forecasting tournament โ one season, one metric, margin unstated, ranking unverified by this publication. The structural point is not the flu result itself but what produced it: ERA, a tool that generates optimization algorithms and is now moving to trusted testers after a Nature publication. A domain win is a data point; a method-writer that produces domain wins is a different kind of asset.
One season does not establish that, and neither does this article. It establishes that the question is now worth asking out loud.
Sources: Google Research Blog, September 30, 2026. CDC FluSight evaluation page returned a 403 at time of publication; the tournament ranking cited here rests on Google’s own account. Nothing in this article is medical advice or investment advice. Alphabet is a publicly listed company.
Every detail above comes from Google’s own research blog post by Zahra Shamsi, dated 30 September 2026, read directly. The CDC’s FluSight evaluation page returns a 403 to this publication, so the ranking has not been checked independently and rests on Google’s account of a public tournament.This is a forecasting result and nothing more. Nothing above claims any effect on patient care, hospital preparedness, public-health response or clinical practice, and nothing above is medical advice or advice about influenza.
The result covers the 2025-26 season only, measuring US hospital admissions at the current week and three weeks ahead. The post does not give the margin over second place, the scoring metric used, the identity of the other 38 eligible models, or performance in any earlier season, so the size of the win is not established here — only its rank.The post describes ERA as generating optimisation algorithms across a range of scientific fields, but a single public result in a single field does not establish that it generalises, and nothing above claims it will or that it outperforms human method design.
The observation that the post lists no caveat of its own is an observation about the post, not a finding about the work. Also absent: ERA’s internal method, the identity of the trusted testers, and whether the model is deployed anywhere operationally. Alphabet is a listed company. Nothing above predicts anything, and nothing here is investment advice.
Gennaro Cuofano is a CRO and tech executive who has worked in AI since late 2015, starting with bringing NLP, natural-language generation, voice and chatbot products to the marketing industry. His background is in law and finance: he holds a Master's degree in Law and an International MBA with an emphasis on corporate finance (LUISS Business School and the University of San Diego, 2012), and worked as a financial analyst at a real-estate investment firm in San Diego and as an assistant controller. His work focuses on business model strategy, business engineering and, more broadly, structural analysis: how companies make money, read from their own filings. He created FourWeekMBA and leads research there and at The Business Engineer, his newsletter on AI and business strategy, with over 95,000 subscribers and more than 1,000 published analyses. His writing has also appeared on Entrepreneur (for example, How to Digitize a Family Business in Europe) and HackerNoon. Find him on LinkedIn and Substack. See how we source.
Scroll to Top
Discover more from FourWeekMBA
Subscribe now to keep reading and get access to the full archive.
